• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Innate Pharma S.A. - American Depositary Shares (NQ:IPHA)

    1.895 -0.080 (-4.05%)
    Streaming Delayed Price Updated: 3:38 PM EDT, Jun 13, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 12,580
    Open 1.960
    Bid (Size) 1.750 (1)
    Ask (Size) 2.180 (2)
    Prev. Close 1.975
    Today's Range 1.871 - 1.980
    52wk Range 1.290 - 3.511
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Innate Pharma Highlights Preclinical Antitumor Activity of IPH6501 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma at the 2025 European Hematology Association (EHA) Congress
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Announces Its Participation in Jefferies and Goldman Sachs Healthcare Conferences
    From Innate Pharma SA
    Via Business Wire

    Performance

    YTD
    +1.3%
    +1.3%
    1 Month
    -8.9%
    -8.9%
    3 Month
    -5.2%
    -5.2%
    6 Month
    -37.3%
    -37.3%
    1 Year
    -20.1%
    -20.1%

    More News

    Read More
    Outcome of Innate Pharma’s 2025 Annual General Meeting
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Highlights Durable Responses to Lacutamab in Sezary Syndrome and Mycosis Fungoides
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Highlights Abstracts Selected for ASCO 2025 Annual Meeting
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Highlights ANKET® Abstracts Selected for the EHA 2025 Congress
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Reports First Quarter 2025 Business Update and Financial Results
    From Innate Pharma SA
    Via Business Wire
    Number of Shares and Voting Rights of Innate Pharma as of May 5, 2025
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma announces conference call and webcast for Q1 2025 business update
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Files Its 2024 Universal Registration Document (Document d’enregistrement universel) and 2024 Annual Report on Form 20-F
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Highlights Preclinical Anti-Tumor Efficacy Data of Its Antibody Drug Conjugate IPH4502 at the AACR 2025 Annual Meeting
    From Innate Pharma SA
    Via Business Wire
    Number of Shares and Voting Rights of Innate Pharma as of April 25, 2025
    From Innate Pharma SA
    Via Business Wire
    French Drugmaker Sanofi Clocks 20% Q1 Profit Growth, Forecasts Strong Rebound In Annual Profit
    Via Benzinga
    Innate Pharma Announces €15M Investment by Sanofi
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Regains Its Rights on CD123 Targeting ANKET® and Announces Sanofi’s Intention to Make a Strategic Investment in the Company
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Proposes to Its Shareholders to Transform Its Corporate Governance Structure Into a Board of Directors and to Change Its Composition
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 22, 2025
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma to Participate in the 2025 Stifel Virtual Targeted Oncology Forum
    From Innate Pharma SA
    Via Business Wire
    Earnings Scheduled For March 27, 2025
    Via Benzinga
    Innate Pharma Reports Full Year 2024 Financial Results and Business Update
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Highlights Antibody Drug Conjugate IPH4502 Abstract Selected for the AACR 2025 Annual Meeting
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma announces its participation in the Life Sciences Van Lanschot Kempen Conference
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma Announces Conference Call and Webcast for Full Year 2024 Financial Results
    From Innate Pharma SA
    Via Business Wire
    Innate Pharma to Participate in the 2025 Leerink Partners Global Healthcare Conference
    From Innate Pharma SA
    Via Business Wire
    Wondering what's happening in today's pre-market session?
    Via Chartmill

    Frequently Asked Questions

    Is Innate Pharma S.A. - American Depositary Shares publicly traded?
    Yes, Innate Pharma S.A. - American Depositary Shares is publicly traded.
    What exchange does Innate Pharma S.A. - American Depositary Shares trade on?
    Innate Pharma S.A. - American Depositary Shares trades on the Nasdaq Stock Market
    What is the ticker symbol for Innate Pharma S.A. - American Depositary Shares?
    The ticker symbol for Innate Pharma S.A. - American Depositary Shares is IPHA on the Nasdaq Stock Market
    What is the current price of Innate Pharma S.A. - American Depositary Shares?
    The current price of Innate Pharma S.A. - American Depositary Shares is 1.895
    When was Innate Pharma S.A. - American Depositary Shares last traded?
    The last trade of Innate Pharma S.A. - American Depositary Shares was at 06/13/25 03:38 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.